Health Condition 1: D758- Other specified diseases of bloodand blood-forming organs
Conditions
Interventions
Intervention1: Cap Thalidomide: Dose: [50 mg/day for adults and 2 mg/kg/day for children] with prospective increase to 100 mg/day for adults and 5 mg/kg/day for children.
Duration: 12 months
Control
Sponsors
ndian Council of Medical Research
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed to have non-transfusion dependent thalassemia [NTDT] 2. Patients not on treatment/on treatment for less than 1 month 3. No major organ dysfunction [grade 3-4 heart, lungs, liver, kidneys]
Exclusion criteria
Exclusion criteria: 1. Diagnosis of thalassemia major 2. Patients on treatment for more than 1 month 3. Unwilling to sign consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of hematological parameters and reducing transfusion frequency in patients with NTDT.Timepoint: Response assessments at 3,6 ,9 and 12 months of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Identification of genetic markers that predict Thalidomide responsiveness in NTDT patients through comparative genomic analysis of responders and non-responders.Timepoint: Response assessments at 3,6 ,9 and 12 months of treatment | — |
Countries
India
Contacts
Public ContactBiju George
Christian Medical College Vellore Ranipet campus,
Outcome results
None listed